Abstract
Current medical treatment of coronary artery disease (GAD) consists of interventions to increase coronary artery flow, reduce myocardial oxygen demand, prevent coronary artery thrombosis, and lyse existing coronary artery thrombi. The strategies used depend on the patient’s ischemic syndromes. Patients with CAD may present to the physician with stable angina, unstable angina, myocardial infarction, or silent ischemia. To a physician seeing a CAD patient for the first time, the disease may manifest itself in any one of the mentioned syndromes. Over a period of time, most patients will experience a change from one syndrome to another. Although the physician cannot eliminate CAD in a patient, the goal of therapy is to keep the patient in a stable state consistent with the best quality of life and the lowest risk from either myocardial infarction or death. Patients are at lowest risk when they are free from ischemia, whether symptomatic or silent, or are in a state of stable angina with symptoms that are infrequent and brought on only by moderate to severe exertion.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Diamond GA, Forester JS. Analysis of probability as an aid in the clinical diagnosis of coronary artery disease. N Engl J Med. 1979;300:1350–1358.
Physicians Health Study Research Group. Fiscal report on the aspirin components of the ongoing Physicians’ Heath Study. N Engl J Med. 1989;321:129–135.
Mansm JE, Grobbee DE, Stampfer MJ, et al. Aspirin in the primary prevention of angina pectoris in a randomized trial of United States physicians. Am J Med. 1990;89:772–776.
Ridker PM, Mansom JE, Gaziahom M, Barihg JE, Hennekens CH. Low-dose aspirin therapy for chronic stable angina. Ann Intern Med. 1991;114:835–839.
Juul-Moller S, Edvardsson N, Jahnmatz B, et al., for the Sweden Angina Pectoris Aspirin Trial (SAPAT) Group. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable angina pectoris. Lancet 1992;340:1421–1425.
Brown BG, Bolson E, Petersen RB, Pierce CD, Dodge HT. The mechanisms of nitroglycerin actin: stenosis vasodilation as a major component of the drug response. Circulation. 1981;64:1089–1097.
Wilkins RW, Hayes FW, Weiss S. The role of the venous system in the circulatory collapse induced by sodium nitrite. J Clin Invest. 1937;85:85–91.
Horowitz JD, Antman EM, Lovell BG, et al. Potentiation of the cardiovascular effects of nitroglycerin by N-acetylcysteine. Circulation. 1983;68:1247–1253.
Murad F. Cyclic guanosine monophosphate as a mediator of vasodilation. J Clin Invest. 1986;78:1–5.
Behovic JL, Bouvier M, Caron MG, Lefkowitz RJ. Regulation of adenylcyclase-coupled beta-adrenergic receptors. Annu Rev Cell Biol. 1988;4:405–428.
Lefkowitz RJ, Caron MG. Adrenergic receptors: models for the study of receptors coupled to guananine nucleotide regulatory proteins. J Biol Chem. 1988;263:4993–4996.
Cruickshank JM. The clinical importance of cardioselectivity and lipophilicity in beta blockers. Am Heart J. 1980;100:160–178.
Braunwald E. Calcium-channel blockers: pharmacologic considerations. Am Heart J. 1982;104:665–671.
Schwartz A, Matlib A, Balwierezak J, Lathrop DA. Pharmacology of calcium antagonists. Am J Cardiol. 1985;55:3c–7c.
Flekenstein A. Specific pharmacology of calcium mycocardium, cardiac pacemakers, and vascular smooth muscles. Annu Reu Pharmacol Toxicol. 1977;17:149–166.
Ellrodt G, Chew CYC, Singh BN. Therapeutic implications of slow-channel blockade in cardiocirculatory disorders. Circulation. 1980;62:669–679.
Singh BN, Nademanee K, Baky S. Calcium antagonist. Drugs. 1983;25:125–153.
Yusef S, Peto R, Lewis J, Collins R, Sleight P. β-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335–371.
Brown BG, Fuster V. Impact of management of stabilization of coronary disease. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and Coronary Artery Disease. Philadelphia, Pa: Lippincott-Raven; 1996:191–205.
Chin JH, Azhar S, Hoffman BB. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest. 1992;89:10–18.
National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;89:1329–1445.
Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990’s. Nature. 1993;362:801–809.
Kyrle Pa, Eicler HG, Jager U, Lechner K Inhibition of prostacyclin and thromboxane A2 generation by low-dose aspirin at the site of plug formation in man and in vivo. Circulation. 1987;75:1025–1029.
Patrignani P, Pilabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low dose aspirin in healthy subjects. J Clin Invest. 1982;69:1366–1372.
Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med. 1989;321:129–135.
Fitzgerald GA. Dipyridamole. N Engl J Med. 1983;316:1247–1257.
International Anticoagulant Review Group. Collaborative analysis of long-term anticoagulant administration after acute myocardial infarction. Lancet. 1970;1:203–209.
Sixty-Plus Reinfarction Study Research Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet. 1980;2:989–994.
Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction. N Engl J Med. 1990;323:147–152.
Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term oral anti-coagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;343:499–503.
Morel DW, DiCorleto PE, Chisolm GM. Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Arteriosclerosis. 1984;4:357–364.
Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoproteins that increase its atherogenicity. N Engl J Med. 1989;320:915–924.
Aviram M. Modified form of low density lipo-protein and atherosclerosis. Atherosclerosis. 1993;98:1–9.
Parthasarathy S, Young SG, Witztum JL, Pittman RC, Steinberg D. Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest. 1986;77:641–644.
Daugherty A, Zweifel BS, Schofeld G. Probucol attenuates the development of aortic atherosclerosis in cholesterolfed rabbits. Br J Pharmacol. 1989;98:612–618.
Anderson TJ, Meredith IT, Charbonneau F, et al. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation. 1996;93:1647–1650.
Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willete WC. Vitamin E consumption and the risk of coronary artery disease in women. N Engl J Med. 1993;328:1444–1449.
Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Coldiz GA, Willete WC. Vitamin E consumption and the risk of coronary disease in men. N Engl J Med. 1993;328:1450–1456.
Kushi LH, Folsom AR, Prineas RJ, Mink PJ, Wu Y, Bostick RM. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med. 1996;334:1156–1162.
Gaziano JM, Manson JE, Buring JE, Hennekens CH. Dietary antioxidants and cardiovascular disease. Ann N Y Acad Sci. 1992;669:249–259.
Henneken CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta-carotene on incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996;334:1145–1149.
The Alpha-Tacopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994;330:1029–1035.
Braunwald E. Unstable angina: a classification. Circulation. 1989;80:410–414.
Clinical Practice Guideline Number 10: Unstable Angina: Diagnosis and Management. Rockville, Md: US Department of Health and Human Services, Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute; 1994. AHCPR publication 94-0602.
Sherman CT, Litvack F, Grundfest W, et al. Coronary an-gioscopy in patients with unstable angina pectoris. N Engl J Med. 1986;315:913–919.
Maseri A, L’Abbate A, Baroldi G, et al. Coronary vasospasm as a possible cause of myocardial infarction: a conclusion derived from the study of “preinfarction” angina. N Engl J Med. 1978;299:1271–1277.
Lewis HD Jr., Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med. 1983;309:396–403.
Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. N Engl J Med. 1985;313:1369–1375.
Theroux P, Qiumet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319:1105–1111.
RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990;336:827–830.
Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine: a controlled multicenter clinical trial. Circulation. 1990;82:17–26.
Theroux P, Waters D, Qui S, McCans J, De Guise P, Juneau M. Aspirin vs heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation. 1993;88(pt 1):2045–2048.
TIMI IIIA Investigators. Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest. Circulation. 1993;87:38–52.
Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease, II: unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA. 1988;260:2088–2093.
Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ. 1989;299:1187–1192.
Lubsen J, Tijssen JG. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/Metoprolol Trial (HINT). Am J Cardiol. 1987;60:18A–25A.
TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q wave myocardial infarction: results of the TIMI IIIB Trial. Circulation. 1994;89:1545–1556.
Luchi RJ, Scott SM, Deupree RH, Principal Investigators, and Their Associates of Veterans Administration Cooperative Study No. 28. Comparison of medical and surgical treatment for unstable angina pectoris. N Engt J Med. 1987;316:977-984.
Russell RO, Moraski RE, Kouchokos N, et al. Unstable angina pectoris: National Cooperative Study Group to compare surgical and medical therapy, II: in-hospital experience and initial followup results in patients with one, two, and three vessel disease. Am J Cardiol. 1978;42:839–848.
Mark DB, Brauwald E. Medical treatment of unstable angina. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and Coronary Artery Disease. Philadelphia, Pa: Lippincott-Raven; 1996:1315–1326.
Davis M, Thomas A. Plaque fissuring: the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J. 1985;53:363–373.
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected myocardial infarctions: ISIS-2. Lancet. 1988;2:349–360.
Yusuf S, Lewis J, Collins R, Sleight P. Beta-blockade during and after acute myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335–371.
Peter T, Norris RM, Clarke ED, et al. Reduction of enzyme release after myocardial infarction in patients by propronolol. Circulation. 1978;57:1091–1095.
Yusuf S, Sleight P, Rossi PRF, et al. Reduction in infarct size, arrhythmias, chest pain, and morbidity by early intravenous blockade in suspected acute myocardial infarction. Circulation. 1983;67(pt 2):32–41.
Norris RM, Barnaby PF, Brown MA, et al. Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol. Lancet. 1984;2:883–886.
Frishman WH, Lazar EJ. Reduction of mortality, sudden death, and non-fatal infarction with beta-adrenergic blockers in survivors of acute myocardial infarction: a new hypothesis regarding the cardioprotective action of beta-adrenergic blockade. Am J Cardiol. 1990;65:66Gñ70G.
ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous atenonol among 16027 cases of suspected myocardial infarction: ISIS-1. Lancet. 1988;2:57–66.
MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI): a randomized placebo controlled international trial. Eur Heart J. 1985;6:199–226.
Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol an acute myocardial infarction: a randomized trial. Lancet. 1981;2:823–827.
Gruppo Italiano per lo Studio della streptochinasi nell’Infarcto Miocardico (GISSI). Effectiveness of intravenous thrombolytic therapy in acute myocardial infarction. Lancet. 1986;1:397–401.
AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet. 1988;1:545–549.
DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980;303:897–902.
Fibrinolytic Therapy Trialist (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet. 1994;343:311–322.
Gruppo Italiano per lo Studio dell Soprawivenza nell’Infarcto Miocardico GISSI-2. A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet. 1990;336:65–71.
ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomized comparison of streptokinase vs tissue plasminogen activator vs anistre-plase and of aspirin plus heparin vs aspirin alone among 41,229 cases of suspected acute myocardial infarction. Lancet. 1992;339:753–770.
GUSTO Investigators. An international randomized trial comparing 4 thrombolytic agents for acute myocardial infarction. N Engl J Med. 1993;329:673–682.
CONSENSUS Trial Study Group. Effects of enalapril on mortality on severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429–1435.
SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med. 1991;325:293–302.
Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after acute myocardial infarction. N Engl J Med. 1992;327:669–677.
Sharpe N, Murphy J, Smith H, Hannan S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet. 1988;1:255–259.
Pfeffer MA, Lamas GA, Vaughan GE, Parisi AF, Braunwald E. Effect of captopril on progressive left ventricular dilatation after anterior myocardial infarction. N Engl J Med. 1988;319:80–86.
Gruppo Italiano per lo Studio della Soprawivenza Nell’Infarcto Miocardio. GISSIS-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function. Lancet. 1994;343:1121–1155.
ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995;345:669–685.
Flather MD, Avezum A, Yusuf S. General approach to management of acute myocardial infarction. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and Coronary Artery Disease. Philadelphia, Pa: Lippincott-Raven; 1996:939–954.
Held P, Yusuf S. Effects of beta-blockers and calcium channel blockers in acute myocardial infarction. Eur Heart J. 1993;14(suppl F):18–25.
Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary artery disease. Circulation. 1995;92:1326–1331.
Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmia drug therapy in acute myocardial infarction. JAMA. 1993;270:1589–1595.
Yusuf S, Flather M. Magnesium in acute myocardial infarction. BMJ. 1995;310:1669–1670.
Glazier JJ, Chierchia S, Brown M, et al. Importance of generalized defective perception of painful stimuli as a cause of silent ischemia in chronic stable angina pectoris. Am J Cardiol. 1986;58:667–672.
Falcone C, Sconnochia R, Guasita L, et al. Dental pain threshold and angina pectoris in patients with coronary artery disease. J Am Coll Cordial. 1988;12:348–352.
Sheps DS, Adams KF, Hinderliter A, et al. Endorphins are related to pain perception in coronary artery disease. Am J Cardiol. 1987;59:523–527.
Falcone C, Guasita L, Ochan M, et al. Beta-endorphins during coronary angioplasty in patients with silent or symptomatic myocardial ischemia. J Am Coll Cardiol. 1993;22:1614–1620.
Marchant B, Umachandran V, Stevenson R, Kopelman PG, Timmis AD. Silent myocardial ischemia: role of subclinical neuropathy in patients with and without diabetes. J Am Coll Cardiol. 1993;22:1433–1437.
Chierchia S, Lazzari M, Freedman B, et al. Impairment of myocardial perfusion and function during painless myocardial ischemia. J Am Coll Cardiol. 1983;1:924–930.
Deanfield JE, Ribiero P, Oakley K, et al. Analysis of ST-segment changes in normal subjects: implications for ambulatory monitoring in angina pectoris. Am J Cardiol. 1984;53:1321–1325.
Deedwania PC, Carbajal EV. Silent ischemia during daily life is an independent predictor of mortality in stable angina. Circulation. 1990;81:748–756.
Weiner DA, Ryan TJ, McCabe CH, et al. Significance of myocardial ischemia during exercise testing in patients with coronary artery disease. Am J Cardiol. 1987;59:725–729.
Gottlieb S, Weisfeldt ML, Ouyang P, Mellitis D, Gersten-blith G. Silent ischemia as a marker for early unfavorable outcome in patients with unstable angina. N Engl J Med. 1986;314:1214–1219.
Nademanee K, Intarachot V, Josephson MA, Rieders D, Mody FV, Singh BN. Prognostic significance of silent myocardial ischemia in patients with unstable angina. J Am Coll Cardiol. 1987;10:1–9.
Romeo F, Rosano GMC, Martuscelli E, Valente A, Reale A. Unstable angina: role of silent ischemia and total ischemic time (silent plus painful episodes), a 6 year follownp. J Am Coll Cardiol. 1992;19:1173–1179.
Cohn PF. Silent ischemia. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and Coronary Artery Disease. Philadelphia, Pa: Lippincott-Raven; 1996:1561–1576.
Lim R, Dyke L, Dymond DS. Effect on prognosis of abolition of exercise-induced painless myocardial ischemia by medical therapy. Am J Cardiol. 1992;69:733–735.
Pepine CJ, Cohn PF, Deedwania PC, et al., for the ASIT Study Group. Effects of treatment on outcome in mildly symptomatic patients with ischemia during life: the Atenolol Silent Ischemia Study (ASIT). Circulation. 1994;90:762–768.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Science+Business Media New York
About this chapter
Cite this chapter
Heng, M.K. (2000). Medical Treatment of Coronary Artery Disease. In: Chang, J.B. (eds) Textbook of Angiology. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-1190-7_18
Download citation
DOI: https://doi.org/10.1007/978-1-4612-1190-7_18
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4612-7039-3
Online ISBN: 978-1-4612-1190-7
eBook Packages: Springer Book Archive